Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 10, 2025
Deals
Sun takes shine to Checkpoint in $355M buyout: Deals Report
Plus: Jazz acquires Chimerix for 72% premium, and J&J does not exercise HexaBody Genmab option, Myokardia ends partnership with Fulcrum
BioCentury | Feb 25, 2025
Emerging Company Profile
Lifordi: Applying ADCs to autoimmune conditions
With $70M series A, biotech backed by Arch, 5am and Atlas is developing a targeted steroid it believes will be safer, with lower and less frequent dosing
BioCentury | Dec 18, 2024
Product Development
Teva-Sanofi showcase best-in-class TL1A potential, without a biomarker
Duvakitug leads to clinical remission in nearly half of UC patients
BioCentury | Nov 19, 2024
Product Development
New oral psoriasis mechanism from Protagonist-J&J yields competitive Phase III data
Also in BioCentury’s latest Clinical Report, CRISPR and RNAi face off in ATTR data from Intellia, Alnylam; plus dermatology setbacks for Incyte
BioCentury | Nov 19, 2024
Deals
More bispecific deals in China: Aclaris/Biosion, Ouro/Keymed, Avenzo/VelaVigo
BioCentury’s Deals Report also includes GSK’s agreement with Flagship-backed Vesalius in Parkinson’s disease, and more
BioCentury | Nov 6, 2024
Distillery Therapeutics
Inhibiting JAK-induced STAT1 signaling for toxic epidermal necrolysis
BioCentury | Oct 21, 2024
Product Development
EGFR: A best-in-class strategy study
The target is one of industry’s most notable case studies in continued product differentiation and market growth
BioCentury | Sep 4, 2024
Discovery & Translation
Immunoproteomics upstage genomics in I&I target discovery
Back to School 2024 identifies the target classes emerging in inflammation and immunology, and the technologies used to find them
BioCentury | Aug 14, 2024
Discovery & Translation
Science Spotlight: Reducing HIV load, new glycopeptide antibiotics, and more
BioCentury’s roundup of translational innovations
Items per page:
1 - 10 of 966